Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics, Inc. (KROS)
:KROS
KROS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.12 - $72.37
Previous CloseN/A
Volume109.28K
Average Volume (3M)1.20M
Market Cap
$576.39M
Enterprise Value$97.48M
Total Cash (Recent Filing)$559.93M
Total Debt (Recent Filing)$18.86M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 01, 2025EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding40,562,046
10 Day Avg. Volume1,618,762
30 Day Avg. Volume1,197,678
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)128.20
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit27.46
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$30.71Price Target Upside116.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Partnerships And DealsKeros Therapeutics shares do not currently reflect any value from attractive economics from their recent deal to advance elritercept, which included significant cash infusion and potential milestone payments.
Strategic AlternativesThe plan to evaluate strategic alternatives and the positive market reaction indicates a proactive approach to utilizing available cash effectively.
Therapeutic DevelopmentKER-065 could serve as a therapy for both adolescent ambulatory and non-ambulatory Duchenne Muscular Dystrophy patients, expanding its potential use.
Bears Say
Clinical DevelopmentThe termination of patient dosing in the Ph2 study of cibotercept in PAH due to adverse events in the lowest dose raises concerns about safety.
Clinical TrialsThe termination of the Phase 2 TROPOS trial of cibotercept due to new adverse events is considered an additional setback for Keros Therapeutics.
Safety ConcernsA dose-dependent hemoglobin increase creates uncertainties in the safety profile of KER-065.
---
Ownership Overview
22.46% Insiders
17.77% Mutual Funds
0.16% Other Institutional Investors
48.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics, Inc.’s price range in the past 12 months?
Keros Therapeutics, Inc. lowest stock price was $9.12 and its highest was $72.37 in the past 12 months.
What is Keros Therapeutics, Inc.’s market cap?
Keros Therapeutics, Inc.’s market cap is $576.39M.
When is Keros Therapeutics, Inc.’s upcoming earnings report date?
Keros Therapeutics, Inc.’s upcoming earnings report date is May 01, 2025 which is in 4 days.
How were Keros Therapeutics, Inc.’s earnings last quarter?
Keros Therapeutics, Inc. released its earnings results on Feb 26, 2025. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.356 by $0.216.
Is Keros Therapeutics, Inc. overvalued?
According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued.
Does Keros Therapeutics, Inc. pay dividends?
Keros Therapeutics, Inc. does not currently pay dividends.
What is Keros Therapeutics, Inc.’s EPS estimate?
Keros Therapeutics, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Keros Therapeutics, Inc. have?
Keros Therapeutics, Inc. has 40,562,046 shares outstanding.
What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?
Keros Therapeutics, Inc. reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.356. Following the earnings report the stock price went up 0.64%.
Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KROS
---
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.71 (116.12% Upside)
$30.71 (116.12% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 384.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.77%
12-Months-Change
Fundamentals
Return on Equity
-41.46%
Trailing 12-Months
Asset Growth
66.44%
Trailing 12-Months
Company Description
Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
---
KROS Stock 12 Month Forecast
Average Price Target
$30.71
▲(116.12% Upside)
Technical Analysis
Theravance Biopharma
―
SAGE Therapeutics
―
Mind Medicine
―
Meiragtx Holdings
―
Tyra Bioscience
―
Best Analysts Covering KROS
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+4.97%
reiterated a buy rating 3 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.97% per trade.
---